Preclinical development of single‑construct short RNAs for systemic delivery that target dozens of cancer‑essential genes and selectively kill tumors without observed normal‑tissue toxicity. Designed to overcome patient and tumor heterogeneity and potentially convert cancer into a chronic‑like condition with periods of complete response or tumor elimination.